ABVC BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
Company: ABVC BioPharma, Inc.
Filing Date: October 8, 2021
Event Date: October 6, 2021 (Completion Date)
Reporting Period: Current Report (Item 1.01 - Entry into a Material Definitive Agreement)
ABVC BioPharma, Inc. entered into a Joint Venture Agreement with Lucidaim Co., Ltd. and BioLite Japan K.K. to formalize their investment and operation of BioLite Japan K.K. ("Biolite"). The joint venture focuses on the research and development of drugs, medical devices, and digital media, as well as the distribution of supplements in Japan and other territories.
Key Financial Metrics and Obligations
This filing does not report consolidated revenue, profit, cash flow, or margins for ABVC BioPharma, Inc. as it is a current report regarding a specific transaction. However, the following financial commitments and structures were disclosed:
- Ownership Structure: Following a share transfer, Lucidaim owns 51% (1,555 shares) and ABVC BioPharma owns 49% (1,494 shares) of Biolite.
- Capital Contributions: ABVC BioPharma paid $100,000 post-Letter of Intent and is obligated to pay an additional $50,000 by the end of the calendar year. Lucidaim paid $150,000.
- Bank Facility: Biolite is required to obtain a facility of JPY 30,460,000 (approx. USD 272,000). ABVC BioPharma guarantees 49% of this facility, representing a potential liability of up to JPY 14,925,400 (approx. USD 134,000).
- Dividends: Biolite shall issue annual dividends at a rate of at least 1.5% of profits if sufficient cash is available.
- Indemnification Limits: Liability caps are set at JPY 500,000 (approx. USD 4,500) for individual liabilities and JPY 2,000,000 (approx. USD 18,000) for aggregate liabilities before indemnification applies.
Material Changes and Transaction Details
The primary material change is the formalization of the joint venture and the adjustment of equity ownership:
- Share Transfer: ABVC BioPharma transferred 54 Ordinary Shares to Lucidaim for no consideration to adjust ownership to 49% and 51% respectively.
- Board Composition: Biolite will have 3 directors: 1 appointed by ABVC BioPharma (Eugene Jiang) and 2 appointed by Lucidaim (Michihito Onishi and Toru Seo).
- License Agreement: The parties agreed to execute a research collaboration and license agreement by the end of December 2021. Negotiations are led by Lucidaim-appointed directors, and Biolite retains the discretion to decline execution without liability to ABVC.
- Related Party Transaction: The transaction was approved by the Board and Audit Committee and is considered a related party transaction conducted at arm's length.
Outlook, Risks, and Contingencies
Management Commentary: The Board believes the joint venture will enhance the Company's ability to provide therapeutic solutions for unmet medical needs, specifically in central nervous system (CNS) and oncology/hematology diseases, and provide access to early-stage product candidates.
Risks and Contingencies:
- License Execution Risk: There is no guarantee the License Agreement will be executed by December 2021, as Biolite may decline to sign without liability.
- Financial Guarantee: ABVC BioPharma is contingently liable for up to USD 134,000 regarding the Biolite bank facility.
- Deadlock Resolution: In the event of a deadlock on "Reserved Matters," a buy-sell mechanism is triggered where one shareholder can offer to buy the other's shares for cash.
- Restrictive Covenants: Non-solicitation and non-compete clauses apply for 2 years post-termination, limited to ophthalmologic and central neurological fields.
- Term: The agreement lasts for 10 years unless terminated earlier by notice or mutual agreement.
Investor Verification Checklist
- Verify the execution status of the License Agreement by the December 2021 deadline.
- Confirm the disbursement of the additional $50,000 capital contribution by ABVC BioPharma.
- Monitor the status of the JPY 30,460,000 bank facility and whether guarantees are invoked.
- Review future filings for updates on the joint venture's R&D progress in CNS and oncology sectors.
- Assess the impact of the 49% ownership stake on future consolidation of Biolite's financial results.